State of New Jersey Common Pension Fund D Acquires 109 Shares of Charles River Laboratories International, Inc. $CRL

State of New Jersey Common Pension Fund D raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,829 shares of the medical research company’s stock after buying an additional 109 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Charles River Laboratories International were worth $2,553,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of CRL. Goldman Sachs Group Inc. boosted its holdings in Charles River Laboratories International by 407.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company’s stock valued at $150,142,000 after acquiring an additional 800,762 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 29.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after purchasing an additional 516,521 shares during the last quarter. Royal Bank of Canada lifted its position in Charles River Laboratories International by 304.7% in the first quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company’s stock valued at $94,484,000 after purchasing an additional 472,606 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Charles River Laboratories International by 144.3% during the first quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company’s stock valued at $82,007,000 after purchasing an additional 321,789 shares during the period. Finally, Wellington Management Group LLP grew its holdings in shares of Charles River Laboratories International by 5.1% in the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock worth $644,980,000 after purchasing an additional 208,586 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on CRL. Mizuho lifted their target price on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. Barclays raised shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $165.00 to $195.00 in a report on Thursday, October 2nd. JPMorgan Chase & Co. upped their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their target price for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Finally, Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and raised their target price for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Eight investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and an average target price of $181.29.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $187.61 on Wednesday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $230.02. The stock’s 50 day simple moving average is $165.77 and its two-hundred day simple moving average is $151.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The stock has a market cap of $9.23 billion, a price-to-earnings ratio of -141.06, a PEG ratio of 5.23 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $983.76 million. During the same quarter last year, the business posted $2.80 EPS. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the transaction, the executive vice president owned 24,116 shares of the company’s stock, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).